This content is machine translated Gastric carcinoma Ways of precision oncology New study data are fundamentally changing first-line treatment of metastatic gastric cancer. The ESMO on Air webinar on March 12, 2025 showed how biomarkers guide therapy selection and open up...…
View Post 8 min This content is machine translated Endometrial Cancer Immunological drivers and new therapeutic pathways Endometrial carcinoma is increasingly becoming the focus of modern tumor immunology as an immunologically characterized tumor disease. Molecular subtypes, microbiome interactions and a highly dynamic tumor immunological microenvironment are opening...…
View Post 8 min This content is machine translated When basal cell carcinomas prove difficult to treat Reaching the goal with innovative therapy strategies The further development of patient-oriented, function-preserving treatment strategies is an important concern of skin cancer research. For patients with advanced cutaneous basal cell carcinoma (BCC), there is a need for...…
View Post 7 min This content is machine translated cSCC: Personalizing Treatment Strategies and Follow-up Care Plans Comprehensive risk stratification is no simple matter: what’s new? Cutaneous squamous cell carcinoma (cSCC) is currently the second most common type of skin cancer, and the number of cases continues to rise. While surgical resection alone is considered the...…
View Post 4 min This content is machine translated Cholangiocarcinoma Modern molecular diagnostics and targeted therapy options Cholangiocarcinoma (CCA) is one of the most aggressive tumors of the hepatobiliary system and is often only diagnosed at an advanced stage. Advances in molecular diagnostics and targeted therapy are...…
View Post 4 min This content is machine translated HER2+ early breast cancer DESTINY-Breast11 – neoadjuvant T-DXd without anthracyclines The phase III DESTINY-Breast11 trial shows that neoadjuvant trastuzumab deruxtecan (T-DXd) could provide an anthracycline-free treatment option for HER2-positive early breast cancer. The results suggest an effective and better tolerated...…
View Post 5 min This content is machine translated Mantle cell lymphoma Recurrence after BTK inhibition – prognostic factors and treatment options Mantle cell lymphoma (MCL) is a rare B-cell non-Hodgkin’s lymphoma with a markedly heterogeneous course. The spectrum ranges from indolent, slowly progressive forms to highly aggressive variants. Diagnosis and treatment...…
View Post 8 min This content is machine translated Urothelial carcinoma Immune and targeted therapy options: Evidence situation 2025/2026 The treatment of urothelial carcinoma has developed significantly in recent years. Modern immunotherapies, antibody-drug conjugates (ADCs) and targeted substances complement conventional chemotherapies and increasingly enable individualized treatment strategies. New data...…
View Post 36 min This content is machine translated Prostate and ovarian cancer Fertility preservation from gonads to genomes to genoids Ovarian and prostate cancers rely on common hormonal, genetic and inflammatory mechanisms that influence both tumor progression and gonadal reproductive function in both sexes; in addition, ovarian stem cell populations...… CME-Test
View Post 14 min This content is machine translated Cardio-oncology When the heart pays for cancer treatment Recent studies show that cardiovascular mortality can become the leading cause of death in cancer survivors over the years. New data on ICI myocarditis, landmark cardioprotection trials and the first...…
View Post 12 min This content is machine translated Prevention and early detection: breast and ovarian cancer Screening strategies, risk genetics and guideline recommendations Breast cancer is the most common cancer in women worldwide – and also the one with the greatest potential for reducing mortality through structured screening. A German long-term study presented...…
